ImmunoGen Inc.
About ImmunoGen Inc.
ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology. The Company's lead product candidate, mirvetuximab soravtansine, is being advanced to Phase 3 testing for FRα-positive platinum-resistant ovarian cancer, and is also in Phase 1b/2 testing in combination regimens for earlier-stage disease. The Company's ADC technology is used in three other clinical-stage ImmunoGen product candidates, in Roche's marketed product, Kadcyla®, and in programs in development by partners Amgen, Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and Takeda.
558 articles with ImmunoGen Inc.
-
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Mar 01, 2021
3/1/2021
ImmunoGen Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that on February 26, 2021 the compensation committee of the Company’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 66,500 shares of its common stock to two employees under the ImmunoGen, Inc.
-
ImmunoGen Announces Webcast of Presentation at Upcoming H.C. Wainwright Virtual Global Life Sciences Conference
2/24/2021
ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller, Chief Financial Officer, and Anna Berkenblit, Chief Medical Officer, will participate in a fireside chat at the upcoming H.C. Wainwright Virtual Global Life Sciences Conference.
-
ImmunoGen Reports Recent Progress and 2020 Financial Results
2/12/2021
ImmunoGen - Top-Line Data from Pivotal SORAYA Trial for Mirvetuximab Soravtansine in Ovarian Cancer Expected in Q3 2021; BLA to be Submitted by Year-End Full Approval Pathway for IMGN632 in BPDCN Aligned with FDA; Updated Phase 1/2 Data in BPDCN Presented at ASH Balance Sheet Funds Operations into the Second Half of 2022 Conference Call to be Held at 8:00 a.m. ET Today
-
ImmunoGen Announces Webcast of Presentation at Upcoming SVB Leerink 10th Annual Global Healthcare Conference
2/11/2021
ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller, Chief Financial Officer, and Anna Berkenblit, Chief Medical Officer, will participate in a fireside chat at the upcoming SVB Leerink 10th Annual Global Healthcare Conference. A webcast
-
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Feb 01, 2021
2/1/2021
ImmunoGen Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that on January 29, 2021 the compensation committee of the Company’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 83,600 shares of its common stock to two four employees under the ImmunoGen, Inc.
-
ImmunoGen Announces Conference Call to Discuss Its 2020 Operating Results
1/29/2021
ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, February 12, 2021 to discuss its 2020 operating results.
-
As the 2021 virtual JP Morgan Healthcare Conference wrapped up, there was still news from companies regarding their deals, pipeline and regulatory updates. Here’s a look.
-
ImmunoGen Announced Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
1/4/2021
ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on December 31, 2020 the compensation committee of the Company’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 91,800 shares of its common stock to two new employees under the ImmunoGen, Inc. Inducement Equity Incentive Plan (the “Indu
-
ImmunoGen Presents Updated Findings from Phase 1/2 Study of IMGN632 in Blastic Plasmacytoid Dendritic Cell Neoplasm at ASH Annual Meeting
12/5/2020
Updated Data Demonstrating Favorable Safety Profile and Encouraging Monotherapy Activity in BPDCN Presented During Oral Session
-
ImmunoGen Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Dec 01, 2020
12/1/2020
ImmunoGen Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that on November 30, 2020 the compensation committee of the Company’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 51,500 shares of its common stock to three new employees under the ImmunoGen, Inc. Inducement Equity Incentive Plan.
-
ImmunoGen Reports Recent Progress and Third Quarter 2020 Financial Results
11/6/2020
Partnership with Huadong Medicine Accelerates Development and Commercialization of Mirvetuximab Soravtansine in Greater China Encouraging Anti-Tumor Activity and Tolerability Data from FORWARD II Triplet Cohort Evaluating Mirvetuximab in Combination with Carboplatin and Avastin ® in Platinum-Sensitive Ovarian Cancer Presented at ESMO FDA Breakthrough Therapy Designation Received for IMGN632 in Relapsed or Refractory BPDCN
-
ImmunoGen Announces Webcast of Presentation at Upcoming Jefferies Virtual London Healthcare Conference
11/4/2020
ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller, Chief Financial Officer, and Anna Berkenblit, Chief Medical Officer, will participate in a fireside chat at the upcoming Jefferies Virtual London Healthcare Conference.
-
ImmunoGen Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Nov 02, 2020
11/2/2020
ImmunoGen, Inc. announced that on October 30, 2020 the compensation committee of the Company’s Board of Directors granted a non-qualified stock option award to purchase an aggregate of 21,500 shares of its common stock to a new employee under the ImmunoGen, Inc.
-
ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2020 Operating Results
10/22/2020
ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, November 6, 2020 to discuss its third quarter operating results.
-
ImmunoGen and Huadong Medicine Announce Strategic Collaboration to Develop and Commercialize Mirvetuximab Soravtansine in Greater China
10/19/2020
Partnership Accelerates Development Path for Mirvetuximab in Greater China and Expands Huadong Medicine’s Oncology Portfolio with Innovative ADC Combines ImmunoGen’s Lead Clinical Program with Huadong’s Regional Oncology Expertise ImmunoGen to Receive $40 Million Upfront Payment and is Eligible to Receive Up to $265 Million in Potential Development, Regulatory, and Commercial Milestone Payments
-
ImmunoGen Raises $54.8 Million in Gross Proceeds Through its At-the-Market Facility
10/12/2020
ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that it has raised gross proceeds of approximately $54.8 million through its At-the-Market (“ATM") facility pursuant to its Open Market Sale Agreement SM dated as of September 25, 2020 with Jefferies LLC, as sales agent (the “Sale Agreement”), with participation based on interest
-
ImmunoGen Announces FDA Breakthrough Therapy Designation for IMGN632 in Relapsed or Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm
10/5/2020
ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation for IMGN632 for the treatment of patients with relapsed or refractory blastic plasmacytoid dendritic cell neoplasm.
-
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct 01, 2020
10/1/2020
ImmunoGen, Inc. announced that on September 30, 2020 the compensation committee of the Company’s Board of Directors granted a non-qualified stock option award to purchase an aggregate of 8,400 shares of its common stock to a new employee under the ImmunoGen, Inc.
-
ImmunoGen Presents Final Data From Phase 1b FORWARD II Triplet Cohort Evaluating Mirvetuximab Soravtansine in Combination With Carboplatin and Avastin® at ESMO
9/17/2020
Triplet Combination Demonstrates Encouraging Anti-Tumor Activity and Tolerability in Recurrent Platinum-Sensitive Ovarian Cancer
-
ImmunoGen Announces Webcast of Presentation at Upcoming H.C. Wainwright Virtual Global Investment Conference - Sep 02, 2020
9/2/2020
ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced that Susan Altschuller, Chief Financial Officer, and Anna Berkenblit, Chief Medical Officer, will present at the upcoming H.C. Wainwright Virtual Global Investment Conference.